Literature DB >> 26185032

Different binding and recognition modes of GL479, a dual agonist of Peroxisome Proliferator-Activated Receptor α/γ.

Jademilson Celestino dos Santos1, Amanda Bernardes1, Letizia Giampietro2, Alessandra Ammazzalorso2, Barbara De Filippis2, Rosa Amoroso2, Igor Polikarpov3.   

Abstract

Peroxisome Proliferator-Activated Receptors (PPARs) are ligand-dependent transcription factors that control various functions in human organism, including the control of glucose and lipid metabolism. PPARγ is a target of TZD agonists, clinically used to improve insulin sensitivity whereas fibrates, PPARα ligands, lower serum triglyceride levels. We report here the structural studies of GL479, a synthetic dual PPARα/γ agonist, designed by a combination of clofibric acid skeleton and a phenyldiazenyl moiety, as bioisosteric replacement of stilbene group, in complex with both PPARα and PPARγ receptors. GL479 was previously reported as a partial agonist of PPARγ and a full agonist of PPARα with high affinity for both PPARs. Our structural studies reveal different binding modes of GL479 to PPARα and PPARγ, which may explain the distinct activation behaviors observed for each receptor. In both cases the ligand interacts with a Tyr located at helix 12 (H12), resulting in the receptor active conformation. In the complex with PPARα, GL479 occupies the same region of the ligand-binding pocket (LBP) observed for other full agonists, whereas GL479 bound to PPARγ displays a new binding mode. Our results indicate a novel region of PPARs LBP that may be explored for the design of partial agonists as well dual PPARα/γ agonists that combine, simultaneously, the therapeutic effects of the treatment of insulin resistance and dyslipidemia.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Crystal structures; Dual agonists; Dyslipidemia; Insulin resistance; Nuclear receptors; PPAR

Mesh:

Substances:

Year:  2015        PMID: 26185032     DOI: 10.1016/j.jsb.2015.07.006

Source DB:  PubMed          Journal:  J Struct Biol        ISSN: 1047-8477            Impact factor:   2.867


  7 in total

1.  Arjunolic acid, a peroxisome proliferator-activated receptor α agonist, regresses cardiac fibrosis by inhibiting non-canonical TGF-β signaling.

Authors:  Trisha Bansal; Emeli Chatterjee; Jasdeep Singh; Arjun Ray; Bishwajit Kundu; V Thankamani; Shantanu Sengupta; Sagartirtha Sarkar
Journal:  J Biol Chem       Date:  2017-08-18       Impact factor: 5.157

2.  Novel Phenyldiazenyl Fibrate Analogues as PPAR α/γ/δ Pan-Agonists for the Amelioration of Metabolic Syndrome.

Authors:  Letizia Giampietro; Antonio Laghezza; Carmen Cerchia; Rosalba Florio; Lucia Recinella; Fabio Capone; Alessandra Ammazzalorso; Isabella Bruno; Barbara De Filippis; Marialuigia Fantacuzzi; Claudio Ferrante; Cristina Maccallini; Paolo Tortorella; Fabio Verginelli; Luigi Brunetti; Alessandro Cama; Rosa Amoroso; Fulvio Loiodice; Antonio Lavecchia
Journal:  ACS Med Chem Lett       Date:  2019-02-25       Impact factor: 4.345

3.  Discovery of a Novel Selective Dual Peroxisome Proliferator-Activated Receptor α/δ Agonist for the Treatment of Primary Biliary Cirrhosis.

Authors:  Zhigan Jiang; Xing Liu; Zhiliang Yuan; Haiying He; Jing Wang; Xiao Zhang; Zhen Gong; Lijuan Hou; Liang Shen; Fengxun Guo; Jiliang Zhang; Jianhua Wang; Deming Xu; Zhuowei Liu; Haijun Li; Xiaoxin Chen; Chaofeng Long; Jian Li; Shuhui Chen
Journal:  ACS Med Chem Lett       Date:  2019-06-24       Impact factor: 4.345

4.  Druggability profile of stilbene-derived PPAR agonists: determination of physicochemical properties and PAMPA study.

Authors:  Pasquale Linciano; Barbara De Filippis; Alessandra Ammazzalorso; Pasquale Amoia; Felisa Cilurzo; Marialuigia Fantacuzzi; Letizia Giampietro; Cristina Maccallini; Charlotte Petit; Rosa Amoroso
Journal:  Medchemcomm       Date:  2019-08-15       Impact factor: 3.597

5.  Perfluoroalkyl Acid Binding with Peroxisome Proliferator-Activated Receptors α, γ, and δ, and Fatty Acid Binding Proteins by Equilibrium Dialysis with a Comparison of Methods.

Authors:  Manoochehr Khazaee; Emerson Christie; Weixiao Cheng; Mandy Michalsen; Jennifer Field; Carla Ng
Journal:  Toxics       Date:  2021-02-26

6.  Structures of PPARγ complexed with lobeglitazone and pioglitazone reveal key determinants for the recognition of antidiabetic drugs.

Authors:  Min A Lee; Lingchen Tan; Huiseon Yang; Yeong-Gwan Im; Young Jun Im
Journal:  Sci Rep       Date:  2017-12-04       Impact factor: 4.379

Review 7.  Current Advances in the Biochemical and Physiological Aspects of the Treatment of Type 2 Diabetes Mellitus with Thiazolidinediones.

Authors:  D Alemán-González-Duhart; F Tamay-Cach; S Álvarez-Almazán; J E Mendieta-Wejebe
Journal:  PPAR Res       Date:  2016-05-23       Impact factor: 4.964

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.